Harpoon Therapeutics (NASDAQ: HARP)

Jounce Therapeutics

This clinical-stage biopharmaceutical company develops immunotherapy treatments for cancer patients by using a platform that enables the immune system to attack tumours.

T-Therapeutics

The company develops T cell receptor therapeutics and bispecific engagers for patients with cancer and autoimmune diseases.

Scorpion Therapeutics

This clinical-stage company develops small-molecule drugs and targeted therapies for patients with various forms of cancer.

Candid Therapeutics

This clinical-stage biotechnology company develops T-cell engager antibodies for patients with autoimmune and inflammatory diseases.

CARGO Therapeutics

This biotechnology company develops engineered cell therapies to treat cancer patients with relapsed or resistant lymphoma.

Daylight Biotherapeutics

This company develops T-cell engaging therapies for cancer patients to eliminate tumours while reducing systemic immune toxicity.

Vittoria Biotherapeutics

This company develops engineered T-cell therapies for patients with cancer and immunological disorders using its proprietary cell manufacturing platform.

Teneobio

This clinical-stage biotechnology company develops human heavy-chain antibodies and multispecific biologics to treat patients with cancers, autoimmune disorders and infectious diseases.